Subconjunctival autologous muscle-derived mesenchymal stem cell therapy: A novel, minimally invasive approach for treating equine immune-mediated keratitis.

The first subconjunctival injection of mdMSCs resulted in improvement of the ocular lesions. Repeated injections were found to be safe, minimally invasive and showed promise in managing refractory cases of equine IMMK. Further studies are warranted to demonstrate the long-term benefits of these injections and to optimize the therapeutic protocol.